1. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
   Kristina M. Ilieva et al, 2018, Frontiers in Immunology CrossRef
2. CA-IX-Expressing Small Extracellular Vesicles (sEVs) Are Released by Melanoma Cells under Hypoxia and in the Blood of Advanced Melanoma Patients
   Marta Venturella et al, 2023, International Journal of Molecular Sciences CrossRef
3. HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
   Anna Lisa Furfaro et al, 2022, Antioxidants CrossRef
4. The regulatory mechanisms of NG2/CSPG4 expression
   Emmanuel Ampofo et al, 2017, Cellular & Molecular Biology Letters CrossRef
5. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer
   Caitlin E. Egan et al, 2021, Thyroid CrossRef
6. Hypoxia-associated markers in the prognosis of oral canine melanoma
   Cecilia Gola et al, 2024, Veterinary Pathology CrossRef
7. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
   C Prieto et al, 2018, Leukemia CrossRef
8. Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression
   Jinfen Wei et al, 2020, International Journal of Molecular Sciences CrossRef
9. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma
   Anna Grossauer et al, 2023, Oncology Letters CrossRef
10. Role of cell surface proteoglycans in cancer immunotherapy
    Nancy A. Espinoza-Sánchez et al, 2020, Seminars in Cancer Biology CrossRef
11. CSPG4: a prototype oncoantigen for translational immunotherapy studies
    Valeria Rolih et al, 2017, Journal of Translational Medicine CrossRef
12. Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment–like Conditions
    Luke Maggs et al, 2020, Clinical Cancer Research CrossRef